Compare
ADC Therapeutics SA vs Eton Pharmaceuticals, Inc. vs Standard Biotools Inc. vs Siga Technologies Inc
| Latest fiscal year | ADC Therapeutics SA ADCT | Eton Pharmaceuticals, Inc. ETON | Standard Biotools Inc. LAB | Siga Technologies Inc SIGA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $81.36M | $79.95M | $85.33M | $94.57M |
| Revenue growth (YoY) | +14.9% | +104.9% | -6.2% | -31.8% |
| Gross margin | 92.9% (computed) | 53.5% | 49.9% | 68.6% (computed) |
| Operating margin | -149.3% | -1.1% | -129.2% | 25.1% |
| Net margin | -175.3% | -5.8% | -87.8% | 24.6% |
| Net income | -$142.62M | -$4.60M | -$74.90M | $23.28M |
| EPS (Diluted) | -$1.12 | n/a | -$0.20 | $0.32 |
| Operating cash flow | -$141.17M | $10.52M | -$74.34M | $43.47M |
| Free cash flow | -$141.44M | $10.19M | -$82.65M | n/a |
| Cash & equivalents | $261.34M | $25.94M | $120.86M | $154.97M |
| Total assets | $323.15M | $92.11M | $567.75M | $219.47M |
| Total liabilities | $508.98M | $65.96M | $143.46M | $20.65M |
| Shareholders' equity | -$185.83M | $26.15M | $424.29M | $198.82M |
| Return on year-end equity | n/a | -17.6% | -17.7% | 11.7% |
| Shares outstanding | 125.75M | 27.05M | 386.38M | 71.61M |
Revenue, most recent five fiscal years
| Fiscal year | ADC Therapeutics SA | Eton Pharmaceuticals, Inc. | Standard Biotools Inc. | Siga Technologies Inc |
|---|---|---|---|---|
| Latest | $81.36M Ended 2025-12-31 | $79.95M Ended 2025-12-31 | $85.33M Ended 2025-12-31 | $94.57M Ended 2025-12-31 |
| 1 year earlier | $70.84M Ended 2024-12-31 | $39.01M Ended 2024-12-31 | $91.01M Ended 2024-12-31 | $138.72M Ended 2024-12-31 |
| 2 years earlier | $69.56M Ended 2023-12-31 | $31.64M Ended 2023-12-31 | $106.34M Ended 2023-12-31 | $139.92M Ended 2023-12-31 |
| 3 years earlier | $209.91M Ended 2022-12-31 | $21.25M Ended 2022-12-31 | $97.95M Ended 2022-12-31 | $110.78M Ended 2022-12-31 |
| 4 years earlier | n/a | $21.83M Ended 2021-12-31 | $130.58M Ended 2021-12-31 | $133.67M Ended 2021-12-31 |